Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections

被引:0
|
作者
Drusano, GL
Craig, WA
机构
关键词
time above MIC; pharmacokinetics; pharmacodynamics;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pharmacodynamic principles that link the concentrations of antibiotics within body systems and their effects have been elucidated only recently. Animal work, now confirmed by clinical studies, has shown that for beta-lactam antibiotics, the time that the serum concentration exceeds the minimum inhibitory concentration (MIC) value of the pathogen is a key parameter in predicting a successful clinical and bacteriological outcome, The situation with the macrolides is less clear; time above MIC is the dynamic variable likely to be most closely linked to efficacy for erythromycin and clarithromycin but for azithromycin it appears to be the area under the plasma concentration-time curve: MIC ratio, Different antibiotics are appropriate for the key pathogens in community-acquired respiratory tract infections, For Streptococcus pneumoniae, amoxycillin/clavulanate is effective with varying dosage regimens providing around 40% time above the MIC90, in contrast to the oral cephalosporins and the macrolides for which serum concentrations do not exceed the MIC90, For Haemophilus influenzae, amoxycillin/clavulanate and cefixime are suitable antibiotics whereas macrolides have limited activity, With the exception of amoxycillin, all the beta-lactam and macrolide antibiotics reviewed here perform better against Moraxella catarrbalis than against the other two principal community-acquired respiratory tract pathogens and there is a wide choice of appropriate agents, Knowledge of the pharmacodynamically-linked variables for different antibiotics allows optimization of dosage regimens and direct comparisons across agents for the same variables.
引用
收藏
页码:38 / 44
页数:7
相关论文
共 50 条
  • [1] Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections
    Andes, D
    Anon, J
    Jacobs, MR
    Craig, WA
    CLINICS IN LABORATORY MEDICINE, 2004, 24 (02) : 477 - +
  • [2] Community-acquired lower respiratory tract infections - Choosing antibiotics for lower respiratory tract infections: pharmacodynamics
    Bedos, JP
    PRESSE MEDICALE, 1998, 27 : 19 - 20
  • [3] Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections
    Kontou, Paschalina
    Chatzika, Kalliopi
    Manika, Katerina
    Pitsiou, Georgia
    Sionidou, Maria
    Kioumis, Ioannis
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [4] Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract
    Wise, R
    Honeybourne, D
    EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (01) : 221 - 229
  • [5] Decalogue for the selection of oral antibiotics for lower respiratory tract infections
    Canton, Rafael
    Barberan, Jose
    Linares, Manuel
    Maria Molero, Jose
    Miguel Rodriguez-Gonzalez-Moro, Jose
    Salavert, Miguel
    Gonzalez del Castillo, Juan
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 (01) : 16 - 29
  • [6] ANTIBIOTICS IN RESPIRATORY TRACT INFECTIONS
    SHAMBAUG.GE
    ARCHIVES OF OTOLARYNGOLOGY, 1965, 82 (06): : 565 - &
  • [7] Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections
    Calbo, E
    Garau, J
    RESPIRATION, 2005, 72 (06) : 561 - 571
  • [8] Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections
    Tanigawara, Yusuke
    Kaku, Mitsuo
    Totsuka, Kyoichi
    Tsuge, Hiroyuki
    Saito, Atsushi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2013, 19 (05) : 858 - 866
  • [9] Upper respiratory tract infections have minimal impact on neffy's pharmacokinetics or pharmacodynamics
    Oppenheimer, John
    Casale, Thomas B.
    Camargo, Carlos A.
    Fleischer, David M.
    Bernstein, David
    Lowenthal, Richard
    Tanimoto, Sarina
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (06): : 1640 - 1643.e2
  • [10] Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections
    Van Wart, S
    Phillips, L
    Ludwig, EA
    Russo, R
    Gajjar, DA
    Bello, A
    Ambrose, PG
    Costanzo, C
    Grasela, TH
    Echols, R
    Grasela, DM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) : 4766 - 4777